Ligand Pharmaceuticals
Ligand Pharmaceuticals

Ligand Pharmaceuticals

Biotechnology
WebsiteInvestor RelationsSEC
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

$6.1B

Market Cap • 10/23/2026

1987

(39 years)

Founded

1994

(32 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

6,3

P/S

20,8

P/EBITDA

47,4

P/OCF

45,9

P/FCF

46

P/E

32,5

BVPS

48,5

EPS

9,4

Market Cap

Market Cap

6,1B

EV

5,8B

EV/Revenue

20

EV/EBITDA

45,6

EV/EBIT

61,5

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,4%

Total Yield

-0,4%

Payout

0%

Retained Earnings

583,3M

Profitability

Gross Margin

95,4%

EBITDA Margin

43,9%

EBIT Margin

32,6%

Net Margin

67,9%

D&A/EBITDA

25,4%

R&D/Revenue

14,2%

Capex/Revenue

0,1%

Capex/D&A

0,8%

Capex/OCF

0,2%

SBC/OCF

40,4%

% PPE

0%

% Goodwill

4,6%

ROE

22%

ROIC

11%

Growth

CAGR Revenue 5Y

2,9%

CAGR Op. Income 5Y

14,7%

CAGR Net Income 5Y

32,7%

CAGR EPS 5Y

27,5%

CAGR OCF 5Y

24,3%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

31,2

Quick Ratio

30,5

Interest Coverage

1530,4%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium